

TARO PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
May 11, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2018

Commission File Number 001-35463

Taro Pharmaceutical Industries Ltd.

(Translation of registrant's name into English)

14 Hakitor Street, Haifa Bay 2624761, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-_____.

Taro Pharmaceutical Industries Ltd.
c/o Taro Pharmaceuticals U.S.A., Inc.
Three Skyline Drive
Hawthorne, New York 10532
(NYSE: TARO)

FOR IMMEDIATE RELEASE

CONTACTS:

| | |
|---------------------------|---|
| Mariano A. Balaguer | William J. Coote |
| VP, CFO | AVP, Business Finance, Treasurer and Investor Relations |
| (914) 345-9001 | (914) 345-9001 |
| Mariano.Balaguer@taro.com | William.Coote@taro.com |

TARO TO ANNOUNCE FULL YEAR RESULTS ON MAY 17, 2018
Earnings Call to Discuss Results to be Conducted Friday, May 18 at 8:00 am EDT

Hawthorne, NY, May 11, 2018 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for year ended March 31, 2018, on Thursday, May 17, 2018.

The Company will conduct an earnings call at 8:00 am EDT on Friday, May 18, 2018, where senior management will discuss the Company's performance and answer questions from participants.

The release will be accessible on Taro's website at www.taro.com.

Earnings Call (8:00 am EDT on Friday, May 18, 2018)

To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.taro.com. A transcript of this earnings call will also be available on the website.

Summary of events

| Event | Date and time | Telephone number/ website |
|---------------------------|---------------------------------|--|
| Earnings release | May 17, 2018 (AMC) | www.taro.com Participant Toll-Free Dial-In Number: +1 (844) 421-0601 Participant International Dial-In Number: +1 (716) 247-5800 |
| Earnings conference call | May 18, 2018 8:00 am EDT | ID: 3249428 Via audio webcast, details of which will be made available on www.taro.com + 1 (855) 859-2056 or +1 (404) 537-3406 |
| Replay of conference call | May 18, 2018 to May 31, 2018 | ID: 3249428 Via audio webcast playback, details of which will be made available on www.taro.com |

About Taro

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 11, 2018

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: /s/ Uday Baldota

Name: Uday Baldota

Title: Chief Executive Officer and Director